246 related articles for article (PubMed ID: 36891226)
1. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Chellapandian D; Milojevic D
Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
Brossard P; Laveille C
Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Hematopoietic Cell Transplant for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.
Davidson N; Rangarajan HG; Driest K; Bajwa RPS; Polishchuk V; Abu-Arja RF
Case Rep Rheumatol; 2021; 2021():9323141. PubMed ID: 34123455
[TBL] [Abstract][Full Text] [Related]
4. Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis.
Morelle G; Castelle M; Pinto G; Breton S; Bendavid M; Boussard C; Mouy R; Bader-Meunier B; Semeraro M; Faye A; Cavazzana M; Neven B; Blanche S; Quartier P; Moshous D
Pediatr Rheumatol Online J; 2021 Mar; 19(1):27. PubMed ID: 33712044
[TBL] [Abstract][Full Text] [Related]
5. Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis.
Beaufils C; Proulx C; Blincoe A; Teira P; Bittencourt H; Cellot S; Duval M; Morin MP; De Bruycker JJ; Couture J; Samaan K; Decaluwe H; Kleiber N; El-Jalbout R; Touzot F; Haddad E; Barsalou J
Front Med (Lausanne); 2023; 10():1275927. PubMed ID: 37908851
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
M F Silva J; Ladomenou F; Carpenter B; Chandra S; Sedlacek P; Formankova R; Grandage V; Friswell M; Cant AJ; Nademi Z; Slatter MA; Gennery AR; Hambleton S; Flood TJ; Lucchini G; Chiesa R; Rao K; Amrolia PJ; Brogan P; Wedderburn LR; Glanville JM; Hough R; Marsh R; Abinun M; Veys P
Blood Adv; 2018 Apr; 2(7):777-786. PubMed ID: 29618462
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia.
Slaney ED; Modica R; Woolnough L; Kafisheh D; Bell-Brunson DH; Elder M
Front Pediatr; 2023; 11():1336554. PubMed ID: 38322244
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of emapalumab in macrophage activation syndrome.
De Benedetti F; Grom AA; Brogan PA; Bracaglia C; Pardeo M; Marucci G; Eleftheriou D; Papadopoulou C; Schulert GS; Quartier P; Antón J; Laveille C; Frederiksen R; Asnaghi V; Ballabio M; Jacqmin P; de Min C
Ann Rheum Dis; 2023 Jun; 82(6):857-865. PubMed ID: 37001971
[TBL] [Abstract][Full Text] [Related]
9. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
[TBL] [Abstract][Full Text] [Related]
10. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
Kostik MM; Isupova EA; Belozerov K; Likhacheva TS; Suspitsin EN; Raupov R; Masalova VV; Chikova IA; Dubko MF; Kalashnikova OV; Chasnyk VG; Cron RQ
Front Pediatr; 2022; 10():894846. PubMed ID: 35967555
[TBL] [Abstract][Full Text] [Related]
11. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
[TBL] [Abstract][Full Text] [Related]
12. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels.
Wakiguchi H; Hasegawa S; Hirano R; Kaneyasu H; Wakabayashi-Takahara M; Ohga S
Pediatr Rheumatol Online J; 2015 Nov; 13():49. PubMed ID: 26581448
[TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
14. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Inoue N; Schulert GS
Arthritis Res Ther; 2023 Mar; 25(1):48. PubMed ID: 36964620
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Fever in a Pediatric Patient: A Case of Systemic Juvenile Idiopathic Arthritis (sJIA) Complicated by Macrophage Activation Syndrome (MAS).
Cortes M; Nudelman BG; Rouse MJ; Frost MD
Cureus; 2023 Sep; 15(9):e46083. PubMed ID: 37900539
[TBL] [Abstract][Full Text] [Related]
16. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
Ambler WG; Nanda K; Onel KB; Shenoi S
Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
[TBL] [Abstract][Full Text] [Related]
17. Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.
Belozerov KE; Solomatina NM; Isupova EA; Kuznetsova AA; Kostik MM
World J Clin Pediatr; 2024 Mar; 13(1):88912. PubMed ID: 38596441
[TBL] [Abstract][Full Text] [Related]
18. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.
Yokota S; Tanaka T; Kishimoto T
Ther Adv Musculoskelet Dis; 2012 Dec; 4(6):387-97. PubMed ID: 23227116
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
